...CYTO ceased operations at its Cellcor Inc. subsidiary, which was developing its autologous lymphocyte therapy (ALT) to...
...carcinoma. CYTO had been in discussions concerning either a management buyout or other sale of Cellcor...
...BioCentury, March 30). CYTO reduced its workforce by 37 employees, including the 23 involved in Cellcor...

...its Cellcor Inc. subsidiary have fallen through and CYTO's board is considering a proposed buyout of Cellcor...

...under development by CYTO's Cellcor Inc. subsidiary, until a partner for the program can be found. Cellcor...
...also is considering selling Cellcor, which it acquired in 1995 (see BioCentury, Oct. 23, 1995). Cellcor...
...was spending $5 million per year. CYTO's burn rate is $1.1 million per month, including Cellcor's...

...who relinquished his positions as CYTO's chairman, president and CEO to become president of CYTO's Cellcor Inc....

...who relinquished his positions as CYTO's chairman, president and CEO to become president of CYTO's Cellcor Inc....

...CYTO's Cellcor subsidiary (Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic...
...Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic colorectal cancer. Cellcor...
...front fee and will record contract revenue on a per patient basis. NEOP will use Cellcor's...

...product using the cell processing and development manufacturing facility in Needham, Mass., operated by CYTO's Cellcor...

...Aug. 17 purchased $20 million of CYTO (Princeton, N.J.) common stock at $3.89 (see Offerings). Cellcor Inc....

...CLTX is in the process of merging with CYTOGEN Corp. (Princeton, N.J.) (see page B2). Cellcor Inc....

...committed to the purchase of at least $12 million of the offering. CYTOGEN Corp. (CYTO) Cellcor Inc....